Asymmetry Capital Management’s Ascendis Pharma A/S ASND Stock Holding History

Asymmetry Capital Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-81,442	Closed	-$12.6M	–	34
2020 Q3	$12.6M	Buy	81,442 +33,843	+71%	+$4.86M	8.08%	1
2020 Q2	$7.04M	Buy	47,599 +19,442	+69%	+$2.67M	5.39%	6
2020 Q1	$3.17M	Buy	28,157 +21,610	+330%	+$2.81M	3.47%	12
2019 Q4	$911K	Buy	+6,547	New	+$727K	1.63%	28
2019 Q3	–	Sell	-3,800	Closed	-$438K	–	25
2019 Q2	$438K	Buy	+3,800	New	+$455K	0.24%	30

Other funds holding ASND

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Asymmetry Capital Management's ASND Position: Q4 2020 in Review

Asymmetry Capital Management sold out of Ascendis Pharma A/S (ASND) in Q4 2020, closing a stake of 81,442 shares — an estimated $12.6M sold.

Asymmetry Capital Management first reported a position in ASND in Q2 2019 and held it in 5 quarters. The position peaked at $12.6M in Q3 2020. 173 funds tracked by Wall St. Rank hold ASND as of Q4 2020.

Asymmetry Capital Management reported no remaining Ascendis Pharma A/S position as of Q4 2020 after selling out during the quarter.
Asymmetry Capital Management sold 81,442 Ascendis Pharma A/S shares in Q4 2020, an estimated $12.6M.
Asymmetry Capital Management first reported a position in Ascendis Pharma A/S in Q2 2019 and held it in 5 quarters.
Asymmetry Capital Management's Ascendis Pharma A/S position peaked at $12.6M in Q3 2020.
173 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2020.

Based on Asymmetry Capital Management's 13F filing for Q4 2020, filed 11 Feb 2021.